Alluvi tirzepatide appears to have emerged as a promising therapeutic option for the control of metabolic disorders. This preclinical evaluation assessed the efficacy and profile of tirzepatide 40mg in in vivo models of insulin resistance. The experiments demonstrated that tirzepatide 40mg significantly improved glycemic management and decreased in